Michelle Conan-Cibotti
Overview
Explore the profile of Michelle Conan-Cibotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Happe M, Lynch R, Fichtenbaum C, Heath S, Koletar S, Landovitz R, et al.
JCI Insight
. 2025 Feb;
10(4).
PMID: 39989458
BACKGROUNDHIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs) have emerged as promising interventions with the potential to effectively treat and prevent HIV-1 infections. We conducted a phase I clinical trial evaluating the...
2.
Awan S, Pegu A, Strom L, Carter C, Hendel C, Holman L, et al.
JCI Insight
. 2024 Apr;
9(7).
PMID: 38587079
BACKGROUNDBroadly neutralizing monoclonal antibodies (bNAbs) represent a promising strategy for HIV-1 immunoprophylaxis and treatment. 10E8VLS and VRC07-523LS are bNAbs that target the highly conserved membrane-proximal external region (MPER) and the...
3.
Houser K, Gaudinski M, Happe M, Narpala S, Verardi R, Sarfo E, et al.
EClinicalMedicine
. 2022 Jul;
48:101477.
PMID: 35783486
Background: Advances in therapeutic drugs have increased life-expectancies for HIV-infected individuals, but the need for an effective vaccine remains. We assessed safety and immunogenicity of HIV-1 vaccine, Trimer 4571 (BG505...
4.
Casazza J, Cale E, Narpala S, Yamshchikov G, Coates E, Hendel C, et al.
Nat Med
. 2022 Apr;
28(5):1022-1030.
PMID: 35411076
Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination or by repeated infusions of bnAbs. In...
5.
Chen G, Coates E, Plummer S, Carter C, Berkowitz N, Conan-Cibotti M, et al.
JAMA
. 2020 Apr;
323(14):1369-1377.
PMID: 32286643
Importance: Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. Objective: To evaluate the safety and tolerability of an investigational CHIKV virus-like...
6.
Gaudinski M, Houser K, Doria-Rose N, Chen G, Rothwell R, Berkowitz N, et al.
Lancet HIV
. 2019 Sep;
6(10):e667-e679.
PMID: 31473167
Background: Human monoclonal antibodies that potently and broadly neutralise HIV-1 are under development to prevent and treat HIV-1 infection. In this phase 1 clinical trial we aimed to determine the...
7.
Gaudinski M, Coates E, Houser K, Chen G, Yamshchikov G, Saunders J, et al.
PLoS Med
. 2018 Jan;
15(1):e1002493.
PMID: 29364886
Background: VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult...
8.
Lynch R, Boritz E, Coates E, DeZure A, Madden P, Costner P, et al.
Sci Transl Med
. 2015 Dec;
7(319):319ra206.
PMID: 26702094
Passive immunization with HIV-1-neutralizing monoclonal antibodies (mAbs) is being considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be used to suppress active virus replication, maintain...